Ulcerative Colitis: Persistence and Colectomy-free Survival With Golimumab vs Adalimumab

Sarfaroj Khan 

Disclosures

November 24, 2020

Takeaway

  • The persistence rates of antitumour necrosis factor agents golimumab and adalimumab as first-line or second-line biologic therapy for ulcerative colitis (UC) were above 64.0% at 12 months following treatment initiation.

  • In addition, the 1-year colectomy-free survival was relatively similar between the 2 treatments.

Why this matters

  • Awareness of the persistence levels observed with adalimumab and golimumab will support appropriate monitoring of patients with UC and better-informed decisions by physicians, with the potential for dose escalation or treatment switching.

Study design

  • This retrospective chart review analysis included 183 adult patients with UC who initiated treatment with golimumab (n=87) or adalimumab (n=96) between 2016 and 2017 using data from 16 National Health Service (NHS) sites in the UK.

  • Primary outcome: treatment persistence rate; secondary outcomes: colectomy-free survival and treatment switching.

  • Funding: None disclosed.

Key results

  • At 12 months following treatment initiation, the persistence rates were 64.6% for adalimumab and 64.4% for golimumab (P=.681).

  • Overall, 37 (20.2%) patients switched to other therapy within 1 year; 15 (8.2%) patients receiving golimumab switched to another biologic compared with 22 (12%) patients receiving adalimumab.

  • Of patients prescribed adalimumab, 14 (14.6%) had ≥1 dose adjustment and the majority (85.7%) had dose escalations.

  • Overall, 15 (8.2%) patients underwent colectomy within 12 months following initiation of golimumab or adalimumab, with no significant difference in colectomy-free survival by treatments (P=.735).

Limitations

  • Retrospective design.

 

Hoque S, Puenpatom A, Boccaletti S, Green C, Black CM, Roberts J, Rajkovic I, Milligan G. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterol. 2020;7(1). doi: 10.1136/bmjgast-2020-000476. PMID: 33199269 View full text

This clinical summary originally appeared on Univadis, part of the Medscape Professional Network.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....